The new DC Universe is two films deep, and the scoreboard reads one hit, one wobble. Superman launched the whole thing in 2025 with a strong 618 million dollars worldwide and a reported 100 million in profit. Supergirl has not had the same liftoff. It opened to just 7.8 million dollars in previews, a figure that includes early fan screenings, against the 22 million Superman pulled the year before. Its opening weekend is now tracking around 40 million domestically, in the neighborhood of Morbius and below The Marvels, and it is losing the number one spot in its own debut frame to the second weekend of Toy Story 5. On a budget reported between 170 and 186 million dollars, with Warner Bros. reportedly hoping for around 300 million worldwide to call it worthwhile, that is a worrying start.
So the universe is one launch and one stumble in, which means the next film carries more weight than it was ever supposed to. And that film is the least likely franchise-saver you could possibly script. It is a hard-R horror movie about a man made of clay.
Meet the DCU’s strangest swing
Clayface is the DCU’s third theatrical entry, and it arrives October 23, 2026, bumped from a September slot to ride the Halloween corridor. This is not a cape movie wearing a spooky coat. It is a full body-horror film, written by horror heavyweight Mike Flanagan of The Haunting of Hill House and Doctor Sleep, with a rewrite by Hossein Amini, and directed by James Watkins of Speak No Evil and Eden Lake.
The cast is loaded: Tom Rhys Harries as Matt Hagen, the doomed actor at the center, with Naomi Ackie as the fringe scientist who transforms him, plus Max Minghella, Eddie Marsan, and Aaron Paul. Matt Reeves, the director of The Batman, produces alongside Lynn Harris and DC bosses James Gunn and Peter Safran. The pitch is pure Hollywood nightmare. A B-movie actor gets his face disfigured, turns in desperation to an Elizabeth Holmes-style scientist, and ends up a shapeshifting creature made of clay. Gunn has flatly called it a complete horror film, and the first trailer, released in April, leaned hard into the body horror.
Why this is smart, and why it is risky
Gunn’s entire thesis for the DCU is that there is no house style. Every film gets to be its own genre, with its own filmmaker’s fingerprints, rather than another variation on the same template. Clayface is the boldest proof of concept yet. If a grisly R-rated horror movie can thrive inside the same universe as the sincere, sunny Superman, that strategy looks visionary.
The timing helps too. Horror is the cheapest, most durable genre in the business, and that late-October window is a proven gold mine, the same stretch that turned It, The Nun, and Beetlejuice into franchises. Crucially, Clayface is a relatively contained, lower-budget film, not a four-quadrant tentpole. It does not need Superman money to count as a win, which makes it a much safer follow-up to a disappointment than another giant would have been. In a strange way, a modest genre play might be exactly the right thing to release after a stumble.
The risk is the narrative. If Clayface underperforms on the heels of Supergirl, the “DCU in trouble” story gets loud in a hurry, fair or not, and a young universe lives and dies by momentum. Two soft films in a row would rewrite the conversation heading into 2027’s Superman: Man of Tomorrow.
The whole universe through a lump of clay
That is why all eyes are quietly shifting to Clayface, and not because it is the safe bet. It is because it is the swing that tells you what kind of universe this is going to be. Superman proved DC can still do the icon. Supergirl raised real doubts about the niche-hero playbook. Clayface tests whether the genre-hopping vision actually holds up when the source material is a Batman villain most moviegoers have never heard of.
It is a deeply weird place to pin a franchise’s hopes. A horror movie about a melting actor, opening near Halloween, asked to steady a billion-dollar universe. Then again, betting on the strange thing instead of the safe thing is the most DCU move imaginable. We will know by November whether it pays off.
